1. Academic Validation
  2. Synthesis and anticancer activity of new benzensulfonamides incorporating s-triazines as cyclic linkers for inhibition of carbonic anhydrase IX

Synthesis and anticancer activity of new benzensulfonamides incorporating s-triazines as cyclic linkers for inhibition of carbonic anhydrase IX

  • Sci Rep. 2022 Oct 6;12(1):16756. doi: 10.1038/s41598-022-21024-7.
Abdelrahman I Zain-Alabdeen 1 Tarek F El-Moselhy 2 Nabaweya Sharafeldin 2 Andrea Angeli 3 Claudiu T Supuran 4 Mervat H El-Hamamsy 2
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, El Giesh Street, Tanta, 31527, Egypt. abdelrahman.ibrahim@pharm.tanta.edu.eg.
  • 2 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, El Giesh Street, Tanta, 31527, Egypt.
  • 3 Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Via U. Schiff 6, 50019, Sesto Fiorentino, Florence, Italy.
  • 4 Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Via U. Schiff 6, 50019, Sesto Fiorentino, Florence, Italy. claudiu.supuran@unifi.it.
Abstract

Limited presence of hCA IX in normal physiological tissues and their overexpression only in solid hypoxic tumors made this isoform excellent possible target for developing new Anticancer agents. We reported designing and synthesis of two novel series of benzenesulfonamides derivatives as hCA IX inhibitors bearing rigid cyclic linkers (1,3,5-dihydrotriazine in series A and 1,3,5-triazine in series B) in replace of traditional linear linkers. Also, novel cyanoethenyl spacer was assembled next to the 1,3,5-triazine linker in series B. Target compounds of series (A) and (B) were screened against four hCA isoforms. Human CA IX efficiently inhibited in series (A) by compound 5a (KI = 134.8 nM). Meanwhile, in series (B) the most active inhibitor was 12i (KI = 38.8 nM). US-NCI protocol was followed to evaluate the Anticancer activity of target compounds against panel of sixty Cancer cell lines. Compound 12d, exposed the best activity towards breast Cancer (MDA-MB-468) with GI% = 62%. The most active analogues, 12d and 12i were further screened for in vitro cytotoxic activity under hypoxic condition against breast Cancer (MDA-MB-468) (IC50 = 3.99 ± 0.21 and 1.48 ± 0.08 µM, respectively) and leukemia (CCRF-CM) cell line (IC50 = 4.51 ± 0.24 and 9.83 ± 0.52 µM, respectively). In addition, 12d arrested breast Cancer MDA-MB-468 cell cycle in G0-G1 and S phases and induced its Apoptosis which indicated by increasing the level of cleaved caspases 3 and 9. Molecular docking was performed for selected analogues to understand their biological alterations. This study revealed that insertion of 1,3,5-triazines as cyclic linkers enhanced the significant Anticancer and hCA IX inhibition activity of benzenesulfonamides.

Figures
Products